Critical Path Institute, through its Type 1 Diabetes Consortium, today reaffirmed its commitment to strengthening the regulatory-science and evidence infrastructure needed to enable the next phase of therapeutic innovation across multiple stages of type 1 diabetes (T1D). The announcement comes in response to the U.S. Food and Drug Administration’s (FDA) accelerated approval last week of Tzield® as the first disease-modifying therapy for stage 3 type 1 diabetes, a milestone achieved by Sanofi, one of several long-standing members of C-Path’s T1D Consortium.

Since 2022, Georgia’s surrogacy industry has boomed, with oversubscribed clinics now recruiting women from across Central Asia via Instagram and TikTok. New research conducted at the University of Oxford’s Centre on Migration, Policy and Society (COMPAS) provides unprecedented insight into the hidden systems of emotional control sustaining Georgia’s transnational surrogacy market.

The Research Centre “Normative Orders” at Goethe University and Suhrkamp Publishing House are hosting an international symposium in memory of philosopher and sociologist Jürgen Habermas, who died in March. Under the title “No One Is Free Until We Are All Free,” leading scholars from Europe and North America will discuss the continuing relevance of his work and the future of Critical Theory.

University of Melbourne researchers have uncovered several animal welfare issues in the United Kingdom’s greyhound racing industry, reigniting public debate about whether the sport should be banned worldwide.